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Mortality estimatesBackground: Multiple factors contribute to variation in disease burden, including the type and quality of
data, and inherent properties of the models used. Understanding how these factors affect mortality esti-
mates is crucial, especially in the context of public health decision making. We examine how the quality
of the studies selected to provide mortality data, influence estimates of burden and provide recommen-
dations about the inclusion of studies and datasets to calculate mortality estimates.
Methods: To determine how mortality estimates are affected by the data used to generate model outputs,
we compared the studies used by The Institute of Health Metrics and Evaluation (IHME) and Maternal
and Child Epidemiology Estimation (MCEE) modelling groups to generate enterotoxigenic Escherichia coli
(ETEC) and Shigella-associated mortality estimates for 2016. Guided by an expert WHO Working Group,
we applied a modified Newcastle-Ottawa Scale (NOS) to evaluate the quality of studies used by both
modelling groups.
Results: IHME and MCEE used different sets of ETEC and Shigella studies in their models and the majority
of studies were high quality. The distribution of the NOS scores was similar between the two modelling
groups. We observed an overrepresentation of studies from some countries in SEAR, AFR and WPR com-
pared to other WHO regions.
Conclusion: We identified key differences in study inclusion and exclusion criteria used by IHME and
MCEE and discuss their impact on datasets used to generate diarrhoea-associated mortality estimates.
Based on these observations, we provide a set of recommendations for future estimates of mortality asso-
ciated with enteric diseases.
 2021 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Estimates of the global burden of morbidity and mortality are
important to help inform decisions on vaccine prioritisation, devel-
opment, introduction and use. Twomodelling groups (The Instituteof Health Metrics and Evaluation (IHME) and the Maternal and
Child Epidemiology Estimation group (MCEE)) have historically
reported mortality estimates for enterotoxigenic Escherichia coli
(ETEC) and Shigella, with modelling results for the same year
tending to show a degree of overlap within those estimates
[1–3]. However, there is some variation in the estimates, both
between the models and iterations within the models [2]. For
2013, MCEE estimated that 42,000 (20,000–76,000) under five year
old (U5) ETEC deaths and 28,000 (12,000–53,000) U5 Shigella
Fig. 1. Steps in IHME and MCEE data collection and processing to generate the estimates for U5 diarrhoea-associated mortality.
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year 2016 (data are currently unpublished). In 2013, IHME was
more consistent with MCEE, estimating that there were 23,100
(17,000–30,400) ETEC- and 33,400 (24,900–43,500) Shigella-
associated U5 deaths [3]. However, in 2016, modelling estimates
for these pathogens by IHME began to show a divergence from
those of MCEE, with 18,669 (9800–30,659) U5 ETEC deaths and
63,713 (41,191–93,611) U5 Shigella deaths [3,5]. Such variations
in pathogen mortality estimates can have implications for future
decision making on vaccine development funding, policy and
uptake and therefore, must be more thoroughly investigated and
understood.
The results presented in this article were generated to evaluate
differences in the modelling outputs of IHME and MCEE groups for
ETEC and Shigella, as recommended by the World Health Organiza-
tion (WHO) Product Development for Vaccines Advisory Commit-
tee (PDVAC) in 2018 [7]. In this article, we look at the studies
that are used to generate the estimates for the two pathogens by
comparing inclusion criteria applied by both groups (Fig. 1, Step
1), investigating the type and quality of studies. We conclude our
findings with a discussion on how studies should be selected for
inclusion in modelling the burden of enteric diseases for future
iterations of mortality estimates. We also present recommenda-
tions for investigators and modellers to further improve study
design and outcome measures.
2. Methods
2.1. Comparison of studies used by IHME and MCEE to calculate U5
mortality estimates
We obtained the lists of studies used by MCEE and IHME to gen-
erate ETEC and Shigella U5 mortality estimates for 2016. We vali-
dated the included studies by re-applying the selection criteria
used by the modelling groups. We cross-checked the included
studies between both groups and noted studies that overlapped.
2.2. The assessment of the quality of studies
Following consultation by a WHO-appointed expert working
group, we generated a grading template by using a modified ver-
sion of the Newcastle-Ottawa Scale (NOS) to assess the quality of
ETEC and Shigella studies included by IHME and MCEE for esti-
mates of etiology-specific U5 mortality. The NOS was designed to
evaluate the quality of non-randomised cohort or case-control
studies based on three main criteria: (1) selection of the study pop-
ulation, (2) comparability of the study population and (3) methods
to ascertain exposure in cohort studies or study outcome in case-
control studies [8]. We modified the NOS to: (1) allow for the4392assessment of cross-sectional studies, (2) to account for the fact
that few studies addressed the exposure to factors associated with
risk for diarrhoeal disease, and (3) to account for the fact that most
of the studies considered the presence of diarrhoeal pathogens as
one of the study outcomes rather than exposure, hence predeter-
mining diarrhoeal disease (Table S1).
The study quality scores were normalised and presented as a
percentage of the maximum possible score. We excluded publica-
tions or datasets that could not be obtained at a level of data strat-
ification required for the analysis, were unpublished at the time of
conducting the analysis, or were published in non-English lan-
guages. The study design of those datasets generated by The Etiol-
ogy, Risk Factors and Interactions of Enteric Infections and
Malnutrition and the Consequences for Child Health and Develop-
ment cohort study (MAL-ED) and the Global Enteric Multicenter
Study (GEMS) that were unpublished at the time the ETEC and Shi-
gella burden of disease estimates for 2016 were made, was graded
using the following publications: Platts-Mills et al., 2015 [9] and
Kotloff et al., 2019 [10]. We visualised the findings using GraphPad
Prism 8 and ArcMap 10.5.
3. Results
3.1. Comparison of studies used by IHME and MCEE to calculate
etiology-specific U5 mortality estimates
Comparison of the study selection criteria used by IHME and
MCEE to generate model inputs for 2016 U5 mortality estimates
found that seven out of ten study selection criteria were unique
to a single group (Table 1). In addition, the groups analysed differ-
ent sets of diarrhoea-associated pathogens. Both groups included
selected pathogens that were associated with diarrhoea in GEMS
qPCR re-analysis [12], however IHME also included Clostridium dif-
ficile (Table 1).
We found that IHME included 44, and MCEE included 7 studies
to generate the ETEC mortality estimates for 2016, and that there
was no overlap in the selection of ETEC studies included by both
groups (Table 2). For Shigella, IHME included 61 studies, while
MCEE selected 31 studies, with only one study used by both groups
being in common (Table 2). This may be attributed to the periods
from which the studies were selected: IHME used studies con-
ducted in 2011–2016 and MCEE included studies published
between 1990 and 2014, the time windows only overlapping for
2011–2014.
3.2. The assessment of the quality of studies
We used the modified NOS to examine the quality of studies
used by both groups. We were unable to assess the quality of 14
Table 1
Overview of criteria used by MCEE and IHME for study selection for 2016 burden of enteric disease estimates.
Inclusion Criteria* MCEE IHME Approach
Sample size Must include at least 100 samples. Same
Introduction of rotavirus vaccines Includes studies conducted before the
introduction of rotavirus vaccines.
Includes studies conducted before and
after the introduction of rotavirus
vaccines.
Different
Inclusion of pathogens Includes selected pathogens that were













Includes selected pathogens that were















Study dates Includes studies published between 1990
and 2014.
Includes studies with recruitment periods
falling within five years before or after the




Possibility to stratify participants by
study setting or hospitalisation
status
Excludes studies which do not stratify
data by inpatient, outpatient or
community settings.
Includes studies which do not stratify data
by inpatient, outpatient or community
settings. Uses non-stratified data and
adjusts for sample population in the
model.
Different
Participant representativeness of the
general population
Excludes studies that report nosocomial,
chronic, antibiotic induced or outbreak
diarrhoea.
Excludes studies that report nosocomial,
chronic, antibiotic induced or outbreak
diarrhoea.
Also excludes studies where population
are non-representative. Except for
Clostridium difficile, where nosocomial
infections are captured but modelling
strategy is different in this instance.
Same except for C. difficile
Type of laboratory methods used to
diagnose the enteric pathogens
Excludes studies which used non-
standard laboratory methods.
Includes studies which used all laboratory
methods.
Different
Studies exploring the presence of
single pathogen only
With the exception of rotavirus, excludes
studies that test for a single pathogen
only.
Includes all studies and applies an
adjustment factor if the data are from
studies that test for a single pathogen
only.
Different
Differentiation of pathogen strains Excludes studies that fail to differentiate
norovirus GI/II, atypical and typical EPEC,
LT/ST-ETEC.
Includes all studies regardless of whether
they differentiate strains or serotypes.
Different
Study duration Excludes studies that last less than 12 months Same
E. Butkeviciute, H.J. Prudden, M. Jit et al. Vaccine 39 (2021) 4391–4398studies (we couldn’t translate ten studies and couldn’t obtain four
studies). Out of the assessed studies, 91% of all ETEC and 87% of all
Shigella studies received quality scores above 70% of a maximumTable 2












used by IHME and
MCEE
ETEC 51 7 44 0
Shigella 91 31 61 1
1 Studies published in 1990–2014 were used to generate MCEE estimates for
2016.
2 Studies with recruitment periods overlapping with 2011–2016 were used to
generate IHME estimates for 2016.
4393obtainable score and were considered high quality studies
(Fig. 2A, B). Of these studies, 51.1% of all ETEC studies and 38.8%
of all Shigella studies received the highest quality score (Fig. 2A,
B). We found that the distribution of all ETEC and Shigella quality
scores between IHME and MCEE was similar (two-tailed p-
value = 0.25 for ETEC studies and p = 0.2813 for Shigella; Wilcoxon
matched-pairs signed rank test). Both ETEC and Shigella studies
were distributed across all WHO regions; however, this distribu-
tion was heterogeneous within regions, resulting in no studies
selected from multiple countries. The low-quality studies (less
than 70% of top obtainable score) were heterogeneously dis-
tributed across the globe.
We also examined the most frequent reasons for studies losing
quality scores. Among ETEC and Shigella studies used by IHME or
MCEE to generate mortality estimates for 2016, the most frequent
reason for losing a quality score was a lack of case definition and
Fig. 2. Distribution of (A) ETEC and (B) Shigella study quality scores for studies used
to generate 2016 burden of enteric disease estimates.
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toms, and inconsistent use of laboratory methods to determine
the aetiology of infection (Table 3).Table 3
Reasons for studies losing a quality score. Numbers in the table indicate number of studi
indicated criteria.
Criterion
Case definition not provided, based on record linkage or patient self-reporting
Exposed group is not representative of the general population (e.g. includes patients
Cases are not representative of the general population (e.g. include patients with chr
Study does not describe how controls were selected (e.g. community, hospital or mix
Sample size <100
Information on missing data or controls not described
Laboratory diagnostic methods are not described or microbiological cause of diarrhoea
patient self-reporting
Laboratory methods are not consistent
Length of follow-up less than 12 months*
Cohort loss to follow-up more than 20% or not reported*
* Cohort studies only.
| Case-control studies only.
43944. Discussion
4.1. Inclusion and exclusion criteria for modelling ETEC and Shigella
mortality estimates
To address the factors that determine the variation in etiology-
specific U5 mortality estimates generated by BoED models using
ETEC and Shigella cases as proxies for diarrhoeal deaths, we exam-
ined the studies used by IHME and MCEE modelling groups and
conducted quality grading analysis.
We found that both modelling groups used different ETEC and
Shigella studies to inform the BoED models, with no commonality
in studies used to generate estimates for ETEC and only one study
used by both groups to model Shigella-attributed U5 mortality in
2016 (Table 2). We also observed that MCEE used fewer ETEC
and Shigella studies compared to IHME. These differences were
likely to reflect the individual strategies on data selection and pro-
cessing used by each group. While both modelling groups included
studies that examined at least 100 samples with a timeframe of
12 months or more (to reduce the chances of pathogen seasonal
variation), other study selection or exclusion criteria differed
between the two groups (Table 1).
The groups applied different approaches towards timeframes
from which the studies were selected. While MCEE included stud-
ies published in 1990–2014 to generate the estimates for 2016,
IHME used studies that had the recruitment period fully or par-
tially overlapping the 5 years immediately before and after the
year for which mortality was estimated (i.e. for 2016 estimates,
studies with a recruitment period falling between 2011 and
2016, until the year the estimates were being made were consid-
ered for inclusion; Tables 1–2). This divergence in timeframes from
which the studies were selected was possibly a critical factor that
contributed to the use of different datasets by both groups (study
periods only overlapped for 2011–2014). Furthermore, while MCEE
used only peer-reviewed published studies, IHME also included
some datasets that were unpublished or published in languages
other than English (which we did not include in the analysis).
We acknowledge that such datasets can contain valuable informa-
tion and suggest identifying unpublished datasets or ongoing stud-
ies where possible to reduce the risk of publication bias, as per
current Cochrane recommendations (Table 4) [13].
Both groups applied different approaches towards data stratifi-
cation. MCEE only selected publications that report inpatient data
to extrapolate information on diarrhoea-associated mortality,
whereas IHME used both inpatient and outpatient data and
adjusted the outpatient data to be representative of the inpatientes used to generate 2016 burden of enteric disease estimates that lost scores for the
IHME MCEE
ETEC Shigella ETEC Shigella
10 23 4 15
with chronic diseases, malignancies)* 1 1 – –
onic diseases, malignancies) 3 4 – –
ed)| – 1 1 1
– – – –
2 3 1 1
is determined by symptomatic reporting, or 1 3 – 1
7 10 3 13
– – – 1
– – – 1
Table 4
Recommendations for inclusion of studies and datasets when conducting mortality estimates for enteric infections.
Purpose of recommendation Audience Recommendation Justification
Reduce the risk of publication bias Modellers Identify unpublished datasets or ongoing studies if possible using systematic
methods such as searching pre-print servers or funders’ databases.
4.1, 4.3
Consider risks associated with use of unpublished data (e.g. datasets that have not
been peer-reviewed).
Consider using studies published in local languages, especially if they pertain to
regions with high burden of enteric diseases or areas where data is limited.
Estimate the contribution of the inherent
properties of BoED models to estimate
variation
Modellers Conduct sensitivity analyses. 4.1
Reduce the risk of bias associated with selection
of cases or overrepresentation of aetiologies
Investigators Use broad case definitions in multiple-pathogen studies. 4.2
Record information on aetiology-associated symptoms or complications as outcomes
of investigation in multiple-pathogen studies to allow stratification of data*.
Modellers Where possible, minimise the need to extrapolate data between populations. If
needed, the extrapolation should be well documented, transparent and tested using
various scenarios.
4.1
Reduce the risk of bias due to the inclusion of
participants that are considered non-
representative
Investigators If study includes participants that are not considered representative of the general
population (e.g. patients with chronic conditions), the data should be presented in a
way that would allow its stratification by factors that affect representativeness.
4.2, 4.3
Modellers Consider subregional or subnational heterogeneity when extrapolating data for areas
where transmission of enteric pathogens may occur in low SES settings localised to
particular areas.
Reduce the risk of bias or variation due to use of
different diagnostic methods
Investigators Use consistent laboratory diagnostic techniques (e.g. use standardised protocols
across multiple study sites; tests compatible across strains or serotypes).
4.2
Provide full information on which diagnostic techniques were used to extract the
data.
Consider use of additional validation methods to differentiate pathogen species
sharing virulence factors (e.g. use of pathogen-selective growth media or serotyping
to differentiate EIEC/Shigella co-detected by PCR).
Modellers Consider stratifying enteric pathogens by serotypes, strains or sub-strains.
Consider strategies used to compile data obtained through conventional and
molecular diagnostic techniques (e.g. model adjustments or weighting of data
acquired through molecular testing).
Consider the effect of enteric pathogen serotypes, strains or sub-strains to estimates
on burden associated with pathogen of interest.
* Excluding single-pathogen studies, investigations on enteric pathogen strains or serotypes, studies on pathology specific to a pathogen or pathogen groups of interest,
settings of interest or types of diarrhoea.
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pitals have more severe symptoms than non-hospitalized patients,
and their distribution of pathogen aetiology reflects the distribu-
tion of aetiology in patients who died. While the extrapolation of
data that represent outpatient populations to inpatient popula-
tions increases data availability, it may also lead to overrepresen-
tation of pathogens that do not normally cause severe disease or
death. Such extrapolations should be minimised where possible,
or when conducted, well documented, transparent and tested
using various scenarios. IHME and MCEE also use different
approaches selecting datasets from studies testing for single or
multiple diarrhoeal pathogens. Single pathogen studies are often
conducted at sites with high pathogen prevalence and overrepre-
sent the true pathogen aetiology [4]. As a result, MCEE excluded
studies where a single pathogen (ETEC or Shigella only) was exam-
ined or different strains of ETEC were not differentiated. IHME
included such studies, adjusting single pathogen studies for over-
representation of aetiology (Table 1).
Differences in data obtained through application of diverse
diagnostic techniques can contribute to variation in diarrhoea-
associated mortality estimates [2,12,14]. While standard labora-
tory methods, such as bacterial culture, microscopy or antigen
immunoassays may lack sensitivity compared to molecular, PCR-
based diagnostics, the latter, despite their sensitivity, may not dis-
tinguish between viable and dead microorganisms [15]. IHME and
MCEE both take different approaches towards use of data obtained
using different laboratory techniques. While MCEE excludes stud-
ies that use non-standard detection methods (accepting both tradi-
tional microbiologic and newer molecular methods), IHME4395includes studies regardless of the detection methods, adjusting
data relative to qPCR findings from GEMS and MAL-ED (Table 1)
[1]. The adjustment for the variation in the use of detection meth-
ods is not conducted by MCEE.
The overall pathogen-specific diarrhoea-associated mortality
can also be affected by pathogen strains or serotypes. This may
be particularly important when generating estimates for ETEC-
associated mortality, as ST-ETEC but not LT-ETEC was found to
be associated with moderate-to-severe diarrhoea [11]. In addition,
inclusion of strains producing different ST toxins was shown to
modify the estimates on proportion of cases attributable to ST-
ETEC [12]. To address the possible issue of estimate variation due
to differential contribution of diarrhoeal pathogen strains, the
modelling groups applied different approaches. While MCEE
excludes studies that do not differentiate between atypical and
typical enteropathogenic E. coli or LT- or ST-ETEC, IHME includes
studies irrespective of whether they differentiate serotypes or
strains (Table 1), adjusting for variation [1].
Considering these different approaches – use of only those epi-
demiological datasets that require as little processing as possible
(generally the MCEE approach) or more diverse data that would
need normalisation through adjustments before using it to gener-
ate the estimates on diarrhoea associated mortality (generally
the IHME approach), it is not surprising that the modelling groups
used different datasets to generate ETEC- and Shigella-associated
mortality for 2016. It is possible that the use of such divergent
datasets may contribute to differences in BoED estimates, although
other factors, such as different modelling strategies, could add to
estimate variation as well. Sensitivity analyses, for instance, testing
Fig. 3. Distribution of studies used in IHME and MCEE models. The map shows countries where (A) ETEC and (B) Shigella studies used by both modelling groups were
conducted to generate estimates for 2016. Colour intensity indicates the number of studies conducted in that country. Striped pattern indicates countries where studies that
received less than 70% of maximum quality score were conducted. Studies conducted at multiple sites (countries) were counted as individual studies per country.
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of different datasets in BoED models, would allow determining
the extent to which differences in datasets or modelling strategies
contribute to estimate variation.4.2. Key insights from the grading analysis and associated
recommendations
To address and compare the quality of studies used by both
groups to generate ETEC and Shigella-attributable mortality in U5
estimates for 2016, we applied the modified NOS and conducted
the grading analysis. No significant differences in the overall distri-
bution of scores were found among ETEC and Shigella studies for
both groups, likely due to the rigorous selection process defined
by the inclusion and exclusion criteria used by each of the mod-
elling groups. The most frequent reasons for losing score for study
quality were a lack of case definition (considered important for
comparability of data) or reliance on patient self-reporting (consid-
ered subjective and susceptible to recall bias); and instances where
a study could not be graded for diagnostic consistency because of
poor description of methods or because data was extracted from
database records (Table 3). Some ETEC studies lost a point for the
consistency of the laboratory methods because of substantial tech-
nological differences in the LT- and ST- toxin detection assays
available at the time the studies were conducted (e.g. adrenal cell
microtiter assay vs DNA hybridisation). We encourage the investi-
gators to use standardised protocols, especially, in multi-site
studies, report their laboratory methods extensively, use supple-
mentary techniques that allow differentiation of pathogens
between species and present their data in a way that would allow
stratification by serotypes, strains or sub-strains (Table 4).
Although most studies used by IHME and MCEE models for
ETEC or Shigella-associated U5 mortality based their definitions
of diarrhoea on the WHO guidelines [16] and examined validated
cases, additional symptoms, such as blood or mucus or consistency
of diarrhoeal stools, their frequency or overall duration were also
often considered when defining inclusion criteria for cases. Such
variation may reflect diversity in study setting or purpose, includ-
ing aetiologies or pathologies of interest [17]. For instance, in
GEMS, moderate-to-severe cases of diarrhoea were recruited, and
patients included those with dysentery diarrhoea [11]. While asso-
ciated with certain types of enteric infections [18], these additional
criteria are highly heterogeneous and may result in bias recruiting
patients with selected aetiologies in multiple-pathogen studies.
We also found that among studies that examined severity of ETEC
or Shigella infections, factors considered associated with severity of
diarrhoea varied, including different combinations of symptoms,
such as fever, vomiting, dysentery, dehydration or requirement
for oral rehydration therapy. Some studies, however, exploited
tools to determine severity of diarrhoea based on clinical symp-
toms, such as the Vesikari scale [19]. While this tool is frequently
used in identifying moderate-to-severe cases of rotavirus-
associated diarrhoea, it can underestimate severity of invasive
diarrhoea, e.g. Shigella infections as they present with different
symptoms [14,20]. We encourage the investigators to use broad
case definitions in multiple-pathogen studies and avoid pre-
selecting cases based on symptoms or complications where it
may introduce over- or underrepresentation of some aetiologies
unless that is necessitated by the hypothesis. We would also
encourage development of more standardised and aetiology-
specific approaches to distinguish severe and milder cases of diar-
rhoea, in the form of guidelines or graded scales (Table 4). Such
tools would allow for higher comparability of data from across dif-
ferent studies and could be useful to measure and compare the
impact of enteric vaccines in trials [14].4397While both groups excluded studies reporting data from partic-
ipants with nosocomial, chronic and antibiotic-induced or
outbreak-associated diarrhoea (Table 1), some studies used to gen-
erate ETEC and Shigella estimates included patients with chronic
conditions, including malignancies and gastrointestinal conditions
or were conducted in settings otherwise not representative of the
general population (e.g. military bases or low socio-economic sta-
tus (SES) communities with lack of access to clean water). It should
be noted that studies on participants with underlying health con-
ditions might be of particular value in settings with high rates of
nosocomial infections; however, if mixed participant populations
are investigated (e.g. in a hospital setting), the data should be pre-
sented in a way that would allow for stratification by the partici-
pant’s status. Regarding studies conducted in low SES settings, it
should be noted that while such communities may be at a higher
risk of enteric disease transmission and contribute to diarrhoea-
associated mortality, their representativeness of region may not
always be appropriate. Indeed, a recent study in 11 eastern and
central African countries showed high sub-national heterogeneity
in ETEC and Shigella-associated mortality, representing potential
for diversity within SES [6].4.3. Geographical representation on ETEC and Shigella-associated
mortality
We examined the distribution of ETEC and Shigella studies used
by IHME and MCEE models to generate the estimates for 2016
(Fig. 3A, B) and found that for both ETEC and Shigella, most studies
were conducted in India, China and Bangladesh in South-East Asian
(SEAR), African (AFR) and Western Pacific (WPR) rerions (Fig. 3,
Table S2). With the exception of China, these countries and regions
have been estimated to have high or moderately high diarrhoea-
associated mortality and benefit from ETEC or Shigella vaccines
[21].
Most countries, however, did not have any ETEC or Shigella
studies included in either IHME or MCEE estimates. Both modelling
groups extrapolate data for regions or countries from which data is
missing: IHME uses GEMS to extrapolate odds ratios and MCEE
uses global medians for pathogen specific proportions [1]. It should
be noted that estimates of ETEC and Shigella-associated mortality
vary not only across countries or regions, but at sub-national level
as well [6], raising concern about a possible risk of under- or
overextrapolation of regional estimates. To increase global BoED
estimate coverage for 2016, both modelling groups used studies
published in local languages. Where appropriate, we encourage
using such studies in line with recommendations for Cochrane sys-
tematic reviews [22] (Table 4).5. Limitations
In this descriptive study, we were unable to determine the
impact of multiple factors on the final U5 etiology-specific diar-
rhoea mortality estimates and their variation such as: inclusion
of unpublished datasets, studies published in non-English lan-
guage, use of low-quality datasets, or change in mortality trends
for ETEC or Shigella. We were also unable to determine the influ-
ence of GEMS or MAL-ED datasets in these models, especially,
where regional diarrhoea-associated U5 mortality estimates were
extrapolated. Similarly, both models included high numbers of
studies from countries with high or moderate burden of diarrhoea,
but we were not able to determine whether abundance of these
studies could bias the global or regional estimates. Some limita-
tions of this work also include the use of the modified NOS as,
despite being based on a template, this tool requires the users to
make subjective interpretations on adequacy of case definitions,
E. Butkeviciute, H.J. Prudden, M. Jit et al. Vaccine 39 (2021) 4391–4398representativeness of controls or cases participating in the study,
and has been reported to lack power in distinguishing confounding
factors [8].
6. Conclusions
This work presents discussion of two different strategies for
modelling U5 diarrhoea-associated mortality estimates: use of
BoED studies that have been through a strict selection process
(MCEE) or through a more inclusive selection of studies, adjusting
for confounding (IHME). We found that both groups used different
sets of studies in their models. While examining the inclusion and
exclusion criteria used by the groups, we found some similarities,
such as required minimal sample size and study duration, although
most criteria defining data stratification, pathogens of interest or
their strains, were different. The most striking difference was the
timeframes from which the studies were selected, overlapping
for years 2011–2014. We predict that this may have contributed
to differences in IHME and MCEE ETEC- and Shigella-associated
U5 mortality estimates in 2016. We also examined the quality of
studies used in these models and found that it was similar. The
most frequent reasons for studies losing quality scores were lack
of case definitions, lack of consistency in laboratory methods or
representativeness of the population or poor description of study
details. We explored the geographical distribution of studies used
in BoED models and found that although datasets from countries
from all WHO regions were used, multiple countries were missing
data. Based on these findings, we prepared a set of recommenda-
tions for the modellers, investigators and policy makers involved
in future BoED estimate generation. Although we used ETEC- and
Shigella-associated U5 mortality estimates as examples, these find-
ings extend to modelling estimates for burden of other infectious
diseases.
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